Dixie‐Lee Esseltine

6.8k citations

38 papers · 3.2k indexed · 2 hit papers · h-index 22

Hematology top 0.2%
- Multiple Myeloma Research and Treatments 35
Oncology top 2%
- Cancer Treatment and Pharmacology 7
- Peptidase Inhibition and Analysis 6
Genetics top 2%
- Chronic Lymphocytic Leukemia Research 6
Molecular Biology top 5%
- Protein Degradation and Inhibitors 23
- Cancer therapeutics and mechanisms 6
- Ubiquitin and proteasome pathways 4
Pathology and Forensic Medicine top 10%
Infectious Diseases
- HIV/AIDS drug development and treatment 7

Co-authors: Paul G. Richardson David P. Schenkein Helgi van de Velde Kenneth C. Anderson Jean‐Luc Harousseau Philippe Moreau William Deraedt Sundar Jagannath
Cited by: Hematology Oncology Genetics
Partner nations: United States United Kingdom France

In The Last Decade

Dixie‐Lee Esseltine

38 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2011 Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
2004 A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

Peers

Countries citing papers authored by Dixie‐Lee Esseltine

Since Specialization

Citations

This map shows the geographic impact of Dixie‐Lee Esseltine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dixie‐Lee Esseltine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dixie‐Lee Esseltine more than expected).

Fields of papers citing papers by Dixie‐Lee Esseltine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dixie‐Lee Esseltine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dixie‐Lee Esseltine. The network helps show where Dixie‐Lee Esseltine may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Dixie‐Lee Esseltine, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Dixie‐Lee Esseltine Line = papers co-authored together Dixie‐Lee Esseltine links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range Michael J. Hanley,Diane R. Mould,Tim Taylor,Neeraj Gupta,Kaveri Suryanarayan,Rachel Neuwirth,Dixie‐Lee Esseltine,Terzah M. Horton,Richard Aplenc,Todd A. Alonzo,Xiaomin Lu,Ashley Milton,Karthik Venkatakrishnan	2017	14
2	Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution Min Tang,Rui Zhao,Helgi van de Velde,Jennifer G. Tross,Constantine S. Mitsiades,Suzanne Viselli,Rachel Neuwirth,Dixie‐Lee Esseltine,Kenneth Anderson,Irene M. Ghobrial,Jesús F. San Miguel,Paul G. Richardson,Michael H. Tomasson,Franziska Michor	2016	20
3	Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials María‐Victoria Mateos,Albert Oriol,Joaquín Martínez‐López,Ana-Isabel Teruel,Enrique Garcíá Bengoechea,Luis Palomera,Felipe de Arriba,Dixie‐Lee Esseltine,Andrew Cakana,Lixia Pei,Helgi van de Velde,Jesús F. San Miguel	2016	19
4	Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918) John P. Leonard,Kathryn S. Kolibaba,James A. Reeves,Anil Tulpule,Ian W. Flinn,Tatjana Kolevska,Robert Robles,Christopher R. Flowers,Robert H. Collins,Nicholas J. DiBella,Steven W. Papish,Parameswaran Venugopal,Andrew Horodner,Amir Tabatabai,Julio Hajdenberg,George Mulligan,Rachel Neuwirth,Kaveri Suryanarayan,Dixie‐Lee Esseltine,Sven de Vos	2015	32
5	Switching from body surface area‐based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis Neeraj Gupta,Yuan Zhao,Ai‐Min Hui,Dixie‐Lee Esseltine,Karthik Venkatakrishnan	2014	47
6	Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials Pieter Sonneveld,Hartmut Goldschmidt,Laura Rosiñol,Joan Bladé,Juan José Lahuerta,Michèle Cavo,Paola Tacchetti,Elena Zamagni,Michel Attal,Henk M. Lokhorst,Avinash Desai,Andrew Cakana,Kevin Liu,Helgi van de Velde,Dixie‐Lee Esseltine,Philippe Moreau	2013	150
7	An Historic Perspective of Proteasome Inhibition Dixie‐Lee Esseltine,George Mulligan	2012	11
8	Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma Philippe Moreau,Ievgenii Karamanesht,Н. П. Домникова,Maryna Kyselyova,Kateryna Vilchevska,Vadim Doronin,Alexander Schmidt,Cyrille Hulin,Xavier Leleu,Dixie‐Lee Esseltine,Karthik Venkatakrishnan,Donna Skee,Huaibao Feng,Suzette Girgis,Andrew Cakana,Helgi van de Velde,William Deraedt,Thierry Façon	2012	68
9	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studybreakdown → Philippe Moreau,Halyna Pylypenko,Sebastian Grosicki,Ievgenii Karamanesht,Xavier Leleu,Maria Grishunina,Grigoriy Rekhtman,Zvenyslava Masliak,Tadeusz Robak,A. V. Shubina,Bertrand Arnulf,Martin Kropff,James Cavet,Dixie‐Lee Esseltine,Huaibao Feng,Suzette Girgis,Helgi van de Velde,William Deraedt,Jean‐Luc Harousseau	2011	661
10	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study Meletios Α. Dimopoulos,María-Victoria Mateos,Paul G. Richardson,Rudolf Schlag,Nuriet K. Khuageva,Ofer Shpilberg,Martin Kropff,Ivan Špıčka,Antonio Palumbo,Ka Lung Wu,Dixie‐Lee Esseltine,Kevin Liu,William Deraedt,Andrew Cakana,Helgi van de Velde,Jesús F. San Miguel	2010	100
11	Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma Paul G. Richardson,Edie Weller,Sundar Jagannath,David Avigan,Melissa Alsina,Robert Schlossman,Amitabha Mazumder,Nikhil C. Munshi,Irene M. Ghobrial,Deborah Doss,Diane Warren,Laura Lunde,Mary McKenney,Carol Delaney,Constantine Mitsiades,Teru Hideshima,William S. Dalton,Robert Knight,Dixie‐Lee Esseltine,Kenneth C. Anderson	2009	127
12	Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm) Antonio Palumbo,Rudolf Schlag,Nuriet K. Khuageva,Ofer Shpilberg,Meletios Α. Dimopoulos,Martin Kropff,Ivan Špıčka,MT Petrucci,Michel Delforge,MV Mateos,Dixie‐Lee Esseltine,K Liu,William Deraedt,H. Van de Velde,Paul G. Richardson,JF San-Miguel	2008	7
13	Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma Sagar Lonial,Paul G. Richardson,Jesús F. San Miguel,Pieter Sonneveld,Michael W. Schuster,Joan Bladé,Jamie Cavenagh,S. Vincent Rajkumar,Andrzej Jakubowiak,Dixie‐Lee Esseltine,Kenneth C. Anderson,Jean‐Luc Harousseau	2008	78
14	Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study. Paul G. Richardson,Sundar Jagannath,Andrzej Jakubowiak,Sagar Lonial,Noopur Raje,Melissa Alsina,Irene M. Ghobrial,Amitabha Mazumder,Nikhil C. Munshi,David H. Vesole,Kathleen Colson,Mary McKenney,Laura Lunde,Sarah J. Kennedy,Kara Kosakowski,Constantine S. Mitsiades,Teru Hideshima,Robert Knight,Dixie‐Lee Esseltine,Kenneth C. Anderson	2008	26
15	Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up Rakesh Popat,Heather Oakervee,Simon Hallam,Nicola Curry,Liz Odeh,Nicola Foot,Dixie‐Lee Esseltine,Mary Drake,Curly Morris,Jamie Cavenagh	2008	101
16	A Phase II Study of Bortezomib (Velcade ®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma William Bensinger,Sundar Jagannath,Robert Vescio,Elber S. Camacho,Jeffrey L. Wolf,David Irwin,Gerardo Capo,Marti McKinley,Phyllis Potts,David H. Vesole,Amitabha Mazumder,Dixie‐Lee Esseltine,Pamela S. Becker,John Crowley,Brian G.M. Durie	2008	20
17	Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia Stefan Faderl,R. Kanti,John G. Gribben,John C. Byrd,Ian W. Flinn,Susan O’Brien,Shihong Sheng,Dixie‐Lee Esseltine,Michael J. Keating	2006	71
18	Bortezomib in Combination with High-Dose Dexamethasone (HD dex) and Erythropoietin (EPO) Does Not Result in an Increased Risk of Thromboembolic Complications. Jean‐Luc Harousseau,Sundar Jagannath,Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,Dixie‐Lee Esseltine,Kenneth C. Anderson	2006	7
19	PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma Heather Oakervee,Rakesh Popat,Nicola Curry,Pat Smith,Curly Morris,Mary Drake,Samir Agrawal,Jim Stec,David P. Schenkein,Dixie‐Lee Esseltine,Jamie Cavenagh	2005	235
20	A phase 2 study of two doses of bortezomib in relapsed or refractory myelomabreakdown → Sundar Jagannath,Bart Barlogie,James R. Berenson,David S. Siegel,David Irwin,Paul G. Richardson,Rubén Niesvizky,Raymond Alexanian,Steven Limentani,Melissa Alsina,Julian Adams,Michael Kauffman,Dixie‐Lee Esseltine,David P. Schenkein,Kenneth C. Anderson	2004	569

About Dixie‐Lee Esseltine

Dixie‐Lee Esseltine is a scholar working on Hematology, Genetics and Oncology, having authored 38 papers that have together received 3.2k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (35 papers), Protein Degradation and Inhibitors (23 papers), HIV/AIDS drug development and treatment (7 papers), Cancer Treatment and Pharmacology (7 papers), Cancer therapeutics and mechanisms (6 papers), Chronic Lymphocytic Leukemia Research (6 papers), Peptidase Inhibition and Analysis (6 papers) and Ubiquitin and proteasome pathways (4 papers). The work is most often cited by research in Hematology (2.5k citations), Oncology (1.6k citations) and Genetics (406 citations). Dixie‐Lee Esseltine has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Paul G. Richardson, David P. Schenkein, Helgi van de Velde, Kenneth C. Anderson, Jean‐Luc Harousseau, Philippe Moreau, William Deraedt, Sundar Jagannath, Melissa Alsina and Rubén Niesvizky.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact